No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
US OptionsDetailed Quotes
GILD250110P77000
- 0.00
- 0.000.00%
15min DelayClose Jan 8 09:30 ET
0.00High0.00Low
0.00Open0.00Pre Close0 Volume0 Open Interest77.00Strike Price0.00Turnover0.00%IV13.62%PremiumJan 10, 2025Expiry Date0.00Intrinsic Value100Multiplier0DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma--Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Intraday
- 5D
- Daily
No Data
News
Morgan Stanley Upgrades Gilead Sciences(GILD.US) to Buy Rating, Raises Target Price to $113
Trump Says World Is Free-Riding on U.S. Health Spending. He Has a Point. -- WSJ
Gilead Sciences: Buy Rating Backed by Promising Pipeline and Attractive Valuation
Express News | Morgan Stanley raised Gilead Sciences' rating to Overweight, with a Target Price of $113.
Gilead Sciences (GILD) Stock Falls Amid Market Uptick: What Investors Need to Know
Pharma Companies Welcome New Year With 583 Drug Price Hikes so Far